PARRY, ROMANI, DECONCINI & SYMMS for INTL ACADEMY OF COMPOUNDING PHARMACISTS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DENNIS DECONCINI | — |
| JAMES ROCK | — |
| ROMANO ROMANI | — |
| THADDEUS E STROM | — |
| STEVE SYMMS | — |
Pharmacy PHA
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DENNIS DECONCINI | — |
| JAMES ROCK | — |
| ROMANO ROMANI | — |
| THADDEUS E STROM | — |
| STEVE SYMMS | — |
Medical/Disease Research/Clinical Labs MED
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DENNIS DECONCINI | — |
| JAMES ROCK | — |
| ROMANO ROMANI | — |
| THADDEUS E STROM | — |
| STEVE SYMMS | — |
Affiliated organisations
| Organisation | Location |
|---|---|
| INTL. ACAD. OF CMPNDING PHARMACISTS | Missouri City, TX, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.